Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chu joins Abingworth's US team

This article was originally published in Clinica

Executive Summary

Life sciences investor Abingworth has expanded its US team with the addition of Shelley Chu as a partner. Chu is a trained doctor and has over 20 years experience in venture capital, business development and strategic leadership. She was most recently at pharma company Gilead Sciences, prior to that, she has worked at Frazier Healthcare Ventures and Flagship Ventures. At Abingworth, Chu will source and manage deals at across a broad range of therapeutic areas and stages of development. Abingworth has investments on both sides of the Atlantic and in pharma and medtech. Its active medtech deals include ophthalmic technology company Avedro and medical imaging firm MEDIAN Technologies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT102940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel